» Articles » PMID: 23371042

International Society of Thrombosis and Hemostasis Scoring System for Disseminated Intravascular Coagulation ≥ 6: a New Predictor of Hemorrhagic Early Death in Acute Promyelocytic Leukemia

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2013 Feb 2
PMID 23371042
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

High-hemorrhagic early death (ED) rate is a major impediment in the managing of acute promyelocytic leukemia (APL). In our group of 56 newly diagnosed APL patients, ED occurred in 12 subjects, due to endocranial bleeding (8/12), differentiation syndrome (2/12), or infection (2/12). Predictors of hemorrhagic ED were as follows: white blood cells count ≥ 20 × 10(9)/L (P = 0.002337), Eastern cooperative oncology group performance status ≥ 3 (P = 0.00173), fibrinogen level <2 g/L (P = 0.004907), prothrombin time <50% (P = 0.0124), and International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation (ISTH DIC score) ≥ 6 (P = 0.00741). Multivariate analysis indicated ISTH DIC score ≥ 6 to be the most significant predictor for hemorrhagic ED (P = 0.008). The main finding of this study is that simple coagulation-related tests, performed on hospital admission and combined in the ISTH DIC score, might help to identify patients at high risk for fatal bleeding needing more aggressive supportive measures.

Citing Articles

Thromboembolism in adult patients with acute promyelocytic leukemia: clinical characteristics, risk factors, and a predictive nomogram.

Hao L, Yao Y, Yang L Ann Hematol. 2025; .

PMID: 39964364 DOI: 10.1007/s00277-025-06251-y.


Risk Factors for Venous Thromboembolism in Acute Promyelocytic Leukemia.

Sabljic N, Pantic N, Virijevic M, Rajic J, Cvetkovic M, Trajkovic L Cancers (Basel). 2025; 16(24.

PMID: 39766107 PMC: 11674958. DOI: 10.3390/cancers16244209.


Hemorrhage in acute promyelocytic leukemia-fibrinolysis in focus.

Sabljic N, Thachil J, Pantic N, Mitrovic M Res Pract Thromb Haemost. 2024; 8(5):102499.

PMID: 39130779 PMC: 11314889. DOI: 10.1016/j.rpth.2024.102499.


Dysregulated hemostasis in acute promyelocytic leukemia.

Hisada Y Int J Hematol. 2024; 119(5):526-531.

PMID: 38341391 DOI: 10.1007/s12185-024-03708-0.


The Coagulopathy of Acute Promyelocytic Leukemia: An Updated Review of Pathophysiology, Risk Stratification, and Clinical Management.

Hermsen J, Hambley B Cancers (Basel). 2023; 15(13).

PMID: 37444587 PMC: 10340352. DOI: 10.3390/cancers15133477.


References
1.
Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y . Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007; 78(3):213-9. DOI: 10.1111/j.1600-0609.2006.00803.x. View

2.
de la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A . Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008; 111(7):3395-402. DOI: 10.1182/blood-2007-07-100669. View

3.
Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103(4):620-5. DOI: 10.7326/0003-4819-103-4-620. View

4.
Taylor Jr F, Toh C, Hoots W, Wada H, Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2002; 86(5):1327-30. View

5.
Jacomo R, Melo R, Souto F, de Mattos E, de Oliveira C, Fagundes E . Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007; 92(10):1431-2. DOI: 10.3324/haematol.10874. View